{
    "clinical_study": {
        "@rank": "164703", 
        "arm_group": {
            "arm_group_label": "MabThera/Rituxan", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, open-label, uncontrolled study will evaluate the safety and\n      pharmacokinetics of MabThera/Rituxan (rituximab) in pediatric patients with severe\n      granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis. Patients will\n      receive MabThera/Rituxan 375 mg/m2 intravenously on Days 1, 8, 15 and 22."
        }, 
        "brief_title": "A Study of Intravenous MabThera/Rituxan in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Wegener's Granulomatosis, Microscopic Polyangiitis", 
        "condition_browse": {
            "mesh_term": [
                "Wegener Granulomatosis", 
                "Systemic Vasculitis", 
                "Microscopic Polyangiitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age at screening between >/= 2 and < 18 years\n\n          -  Diagnosis of granulomatosis with polyangiitis (EULAR/PRINTO/PRES 2008, Ankara\n             criteria for childhood Wegener's granulomatosis) or diagnosis of microscopic\n             polyangiitis (according to the Chapel Hill Consensus Conference)\n\n          -  Newly diagnosed patients or patients with relapsing disease according to the\n             following definition:\n\n        The recurrence or new onset of potentially organ- or life-threatening disease (i.e. one or\n        more major BVAS/WG items as listed in the protocol or disease severe enough to require\n        treatment with cyclophosphamide)\n\n          -  For patients of reproductive potential (males and females), use of reliable means of\n             contraception throughout the study participation\n\n          -  For all eligible patients, mandatory prophylactic treatment for Pneumocystis\n             jirovecii infection\n\n        Exclusion Criteria:\n\n          -  Diagnosis of Churg-Strauss syndrome, as defined by the Chapel Hill consensus\n             Conference (Jennette 1994)\n\n          -  Limited disease that would not normally be treated with cyclophosphamide\n\n          -  Severe disease requiring mechanical ventilation due to alveolar hemorrhage\n\n          -  Requirement for plasmapheresis or dialysis at screening\n\n          -  Pregnancy or breastfeeding\n\n          -  Evidence of other significant uncontrolled concomitant disease, or of disorder or\n             condition that, in the investigator's opinion, would preclude or interfere with\n             patient participation\n\n          -  Primary or secondary immunodeficiency (history of or currently active), including\n             known history of human immunodeficiency virus (HIV) infection\n\n          -  Known active infection of any kind (excluding fungal infections of nail beds), or any\n             major episode of infection requiring hospitalization with IV anti-infective agents\n             within 4 weeks of baseline or completion of oral anti-infective agents within 2 weeks\n             prior to baseline\n\n          -  History of deep space/tissue infection within 24 weeks prior to baseline\n\n          -  History of serious recurrent or chronic infection\n\n          -  History of cancer (except for basal cell and squamous cell carcinoma of the skin that\n             have been excised and cured)\n\n          -  Currently active alcohol or drug abuse or history of alcohol or drug abuse\n\n          -  History of severe allergic or anaphylactic reaction to a biologic agent or known\n             hypersensitivity to any component of rituximab or to murine proteins\n\n          -  Previous treatment with rituximab\n\n          -  Previous treatment with any cell-depleting therapies\n\n          -  Receipt of oral or IV cyclophosphamide within the previous 4 months prior to the\n             baseline visit\n\n          -  Receipt of infliximab within 3 months, adalimumab within 2 months or etanercept\n             within 1 month prior to the baseline visit\n\n          -  Treatment with any investigational agent within 28 days of baseline or 5 half-lives\n             of the investigational drug (whichever is longer)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750697", 
            "org_study_id": "WA25615", 
            "secondary_id": "2012-002062-13"
        }, 
        "intervention": {
            "arm_group_label": "MabThera/Rituxan", 
            "description": "375 mg/m2 iv on Days 1, 8, 15 and 22", 
            "intervention_name": "rituximab [MabThera/Rituxan]", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84109"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bron", 
                        "country": "France", 
                        "zip": "69677"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75743"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20246"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69120"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "Lazio", 
                        "zip": "00165"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "state": "Liguria", 
                        "zip": "16147"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "Lombardia", 
                        "zip": "20122"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "Veneto", 
                        "zip": "35128"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06100"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey", 
                        "zip": "34098"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "United Kingdom", 
                        "zip": "L12 2AP"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "WC1N 1EH"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom", 
                        "zip": "NG7 2UH"
                    }
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Germany", 
                "Italy", 
                "Turkey", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE IIa, INTERNATIONAL, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF 4 x 375 mg/m2 INTRAVENOUS RITUXIMAB IN PEDIATRIC PATIENTS WITH SEVERE GRANULOMATOSIS WITH POLYANGIITIS (WEGENER S) OR MICROSCOPIC POLYANGIITIS", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: WA25615 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Safety: Nature and severity of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Pharmacokinetics: Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "up to Day 22 and at Month 1, 2, 4 and 6"
            }, 
            {
                "measure": "Pharmacokinetics: Volume of distribution", 
                "safety_issue": "No", 
                "time_frame": "up to Day 22 and at Month 1, 2, 4 and 6"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750697"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "up to Day 22 and at Month 1, 2, 4 and 6"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "up to Day 22 and at Month 1, 2, 4 and 6"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}